The REmAb® sequencing service directly de novo sequences antibody proteins without the need for cell lines and DNA. Using high-precision, high-resolution mass spectrometry equipment and an antibody protein sequencing platform with independent research and development and independent intellectual property rights, we have successfully completed thousands of protein sequencing projects and gained trust from more than 200 research institutions worldwide. Rapid Novor is a global leader in antibody protein sequencing. Our WILD® technology is the first high-throughput commercial service that uses mass spectrometry to accurately distinguish between isoleucine and leucine. The accuracy of each amino acid directly ensures the correctness of the results and greatly accelerates the customer’s research and development process.
Jul 30, 2020
Posted by Rapid Novor Inc